{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:51:52Z","timestamp":1790718712903,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010135","name":"Finska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004702","name":"Baxter International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.vaccine.2022.01.022","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T06:08:43Z","timestamp":1643609323000},"page":"1299-1305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Three-dose versus four-dose primary schedules for tick-borne encephalitis (TBE) vaccine FSME-immun for those aged 50\u00a0years or older: A single-centre, open-label, randomized controlled trial"],"prefix":"10.1016","volume":"40","author":[{"given":"Anu","family":"Kantele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Rombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirkka","family":"Vene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lindquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina O.","family":"Erra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.vaccine.2022.01.022_b0005","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.37.30020","article-title":"Surveillance of endemic foci of tick-borne encephalitis in Finland 1995\u20132013: evidence of emergence of new foci","volume":"20","author":"Tonteri","year":"2015","journal-title":"Euro Surveill"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.022_b0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ttbdis.2018.10.008","article-title":"Emergence of tick-borne encephalitis (TBE) in the Netherlands","volume":"10","author":"Dekker","year":"2019","journal-title":"Ticks Tick Borne Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.022_b0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.vaccine.2004.07.002","article-title":"Immunogenicity and safety of a booster vaccination against tick-borne encephalitis more than 3 years following the last immunisation","volume":"23","author":"Rendiwagner","year":"2004","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2022.01.022_b0020","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1016\/j.vaccine.2006.03.061","article-title":"Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies","volume":"24","author":"Loew-Baselli","year":"2006","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.01.022_b0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3201\/eid1901.120458","article-title":"Vaccination and tick-borne encephalitis, central Europe","volume":"19","author":"Heinz","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2022.01.022_b0030","unstructured":"Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol Rec 2011; 86: 241\u201356."},{"key":"10.1016\/j.vaccine.2022.01.022_b0035","doi-asserted-by":"crossref","unstructured":"Lenhard T, Ott D, Jakob NJ, Pham M, B\u00e4umer P, Martinez,Torres F, et al. Predictors, Neuroimaging Characteristics and Long-Term Outcome of Severe European Tick-Borne Encephalitis: A Prospective Cohort Study. PLoS One 2016;11: e0154143. DOI:10.1371\/journal.pone.0154143.","DOI":"10.1371\/journal.pone.0154143"},{"key":"10.1016\/j.vaccine.2022.01.022_b0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.tmaid.2018.10.003","article-title":"Factors associated with severity of tick-borne encephalitis: A prospective observational study","volume":"26","author":"Bogovi\u010d","year":"2018","journal-title":"Travel Med Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.022_b0045","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/joim.12625","article-title":"Tick-borne encephalitis in patients vaccinated against this disease","volume":"282","author":"Lotri\u010d-Furlan","year":"2017","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.vaccine.2022.01.022_b0050","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ttbdis.2018.02.021","article-title":"Clinical outcome and cerebrospinal fluid profiles in patients with tick-borne encephalitis and prior vaccination history","volume":"9","author":"Lenhard","year":"2018","journal-title":"Ticks Tick Borne Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.01.022_b0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.it.2009.05.002","article-title":"Vaccination in the elderly: an immunological perspective","volume":"30","author":"Chen","year":"2009","journal-title":"Trends Immunol"},{"issue":"25","key":"10.1016\/j.vaccine.2022.01.022_b0060","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1016\/j.vaccine.2005.01.085","article-title":"Insufficient protection for healthy elderly adults by tetanus and TBE vaccines","volume":"23","author":"Hainz","year":"2005","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.01.022_b0065","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jmv.23313","article-title":"Persistence of immunity to tick-borne encephalitis after vaccination and natural infection","volume":"84","author":"Baldovin","year":"2012","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.022_b0070","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11357-011-9371-9","article-title":"Mechanistic insights into the impairment of memory B cells and antibody production in the elderly","volume":"35","author":"Aberle","year":"2013","journal-title":"Age (Dordr)"},{"key":"10.1016\/j.vaccine.2022.01.022_b0075","doi-asserted-by":"crossref","unstructured":"Lindblom P, Wilhelmsson P, Fryland L, Matussek A, Haglund M, Sj\u00f6vall J, et al. Factors determining immunological response to vaccination against tick-borne encephalitis virus in older individuals. PLoS One 2014; 9: e100860. DOI:10.1371\/journal.pone.0100860.","DOI":"10.1371\/journal.pone.0100860"},{"issue":"21-22","key":"10.1016\/j.vaccine.2022.01.022_b0080","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.vaccine.2004.01.041","article-title":"Persistence of protective immunity following vaccination against tick-borne encephalitis\u2013longer than expected?","volume":"22","author":"Rendi-Wagner","year":"2004","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.01.022_b0085","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4161\/hv.5.8.8571","article-title":"Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5 ml in adults aged 18\u201367 years","volume":"5","author":"Loew-Baselli","year":"2009","journal-title":"Hum Vaccin"},{"issue":"20","key":"10.1016\/j.vaccine.2022.01.022_b0090","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1016\/j.vaccine.2010.03.024","article-title":"Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50\u201390 years","volume":"28","author":"Weinberger","year":"2010","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.01.022_b0095","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.vaccine.2012.12.075","article-title":"Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination","volume":"31","author":"Paulke-Korinek","year":"2013","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2022.01.022_b0100","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.vaccine.2014.01.072","article-title":"Irregular tick-borne encephalitis vaccination schedules: the effect of a single catch-up vaccination with FSME-IMMUN. A prospective non-interventional study","volume":"32","author":"Schosser","year":"2014","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.vaccine.2022.01.022_b0105","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/j.vaccine.2017.03.059","article-title":"Seropersistence of TBE virus antibodies 10 years after first booster vaccination and response to a second booster vaccination with FSME-IMMUN 0.5mL in adults","volume":"35","author":"Konior","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.022_b0110","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/00365540110027358","article-title":"Pharmacokinetics of human tick-borne encephalitis virus antibody levels after injection with human tick-borne encephalitis immunoglobulin, solvent\/detergent treated, FSME-BULIN S\/D in healthy volunteers","volume":"33","author":"Adner","year":"2001","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.01.022_b0115","unstructured":"TicoVac 0.5 ml Suspension for injection in a prefilled syringe. Summary of Product Characteristics. Updated 06-Nov-2018, Pfizer Limited."},{"key":"10.1016\/j.vaccine.2022.01.022_b0120","doi-asserted-by":"crossref","first-page":"101876","DOI":"10.1016\/j.tmaid.2020.101876","article-title":"Immunogenicity and safety of the tick-borne encephalitis vaccination (2009\u20132019): A systematic review","volume":"37","author":"Rampa","year":"2020","journal-title":"Travel Med Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.022_b0125","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0264-410X(03)00563-2","article-title":"Randomized, phase II dose-finding studies of a modified tick-borne encephalitis vaccine: evaluation of safety and immunogenicity","volume":"22","author":"Ehrlich","year":"2003","journal-title":"Vaccine"},{"issue":"7-8","key":"10.1016\/j.vaccine.2022.01.022_b0130","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0264-410X(98)00272-2","article-title":"Vaccination against tick-borne encephalitis under therapeutic immunosuppression. Reduced efficacy in heart transplant recipients","volume":"17","author":"Dengler","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.022_b0135","unstructured":"Wanke KHL, Mekker A, Steffen R, Stiasny K, Heinz FX, Unger B, Karrer, U. Immunogenicity and safety of tick borne encephalitis vaccination in healthy elderly individuals. In: Proceedings of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), London, UK, 31 March\u20133 April 2012."},{"key":"10.1016\/j.vaccine.2022.01.022_b0140","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1016\/j.vaccine.2016.07.029","article-title":"Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO(R) in elderly subjects: open-label, uncontrolled, multi-center, phase 4 study","volume":"34","author":"Cramer","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.022_b0145","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.vaccine.2015.12.029","article-title":"Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study","volume":"34","author":"Hertzell","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.01.022_b0150","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.vaccine.2006.10.028","article-title":"Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule","volume":"25","author":"Sch\u00f6ndorf","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.01.022_b0155","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.vaccine.2008.11.082","article-title":"Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur Adults","volume":"27","author":"Plentz","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.01.022_b0160","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1016\/j.vaccine.2017.12.081","article-title":"Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10years antibody persistence","volume":"37","author":"Beran","year":"2019","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.01.022_b0165","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/cid\/ciz176","article-title":"Tick-borne encephalitis vaccine failures: a 10-year retrospective study supporting the rationale for adding an extra priming dose in individuals starting at age 50 years","volume":"70","author":"Hansson","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.022_b0170","doi-asserted-by":"crossref","first-page":"101779","DOI":"10.1016\/j.ttbdis.2021.101779","article-title":"Can the booster interval for the tick-borne encephalitis (TBE) vaccine 'FSME-IMMUN' be prolonged? - a systematic review","volume":"12","author":"Steffen","year":"2021","journal-title":"Ticks Tick Borne Dis"},{"issue":"49","key":"10.1016\/j.vaccine.2022.01.022_b0175","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1016\/j.vaccine.2020.10.022","article-title":"Analysis of Tick-borne Encephalitis vaccination coverage and compliance in adults in Switzerland, 2018","volume":"38","author":"Baroutsou","year":"2020","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.01.022_b0180","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.vaccine.2020.12.047","article-title":"Vaccination rate and adherence of tick-borne encephalitis vaccination in Germany","volume":"39","author":"Schley","year":"2021","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:10:35Z","timestamp":1759403435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0264410X22000482"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.022","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-dose versus four-dose primary schedules for tick-borne encephalitis (TBE) vaccine FSME-immun for those aged 50\u00a0years or older: A single-centre, open-label, randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}